The short version of gastric juice protein fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
== Radiology == CT scan (B*2****) magnetic resonance imaging (MRI) (B*3****) nuclear medicine (C******) positron-emission tomography (PET) projectional radiography (B*0****) ultrasonography (B*4****) Alternative list formatting:
== Development history == Before the discovery of SSRI drugs, the treatments for mood disorders were relatively limited. Now, however, there are dozens of antidepressants on the market for the treatment of depression. Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) were the first drugs to be developed for the treatment of depression, dating back to the early 1950s. Because of their undesirable adverse-effect profile and high potential for toxicity, due to their non-selective pharmacological effects, strict regimens were needed for taking the drugs, which limited their use. Because of this, researchers looked for other alternatives with similar effectiveness but fewer adverse effects e.g. drugs that did not cause cardiac conduction abnormalities in overdoses or have the tendency to cause seizures, which led to the discovery of the SSRI drugs. The SSRIs are the most significant class of antidepressants marketed in recent years and are one of the major medicinal discoveries of the last few decades. SSRIs were the first drugs to establish a theoretical pathophysiological role for 5-HT in affective illnesses and in the broad spectrum of anxiety disorders. Likewise, they were the first to confirm the inhibition of neurotransmitter re-uptake as an important therapeutic principle. The SSRIs are the first rationally designed class of psychotropic medications.
=== Relaxing temperature requirements === The typical recommendation of storage 2–8 °C (36–46 °F), often worded as a "requirement" on the label, is mainly derived from the cold chain guideline of the Expanded Program on Immunization as a matter of tradition. Vaccines are not routinely tested for their stability at higher temperatures. In places with unreliable power supply, this leads to doses of vaccines that are potentially still effective being written off when the cold chain is interrupted, or no attempt to supply the vaccine to be even done due to the perceived cost of the cold chain. Similarly, many vaccines carry an unnecessary "do not freeze" instruction. Both WHO and PATH have published compilations on the stability of vaccines beyond the recommended temperature range, specifically for heat and freezing. Studies have found that when vaccines are allowed to go outside the cold chain (OCC), vaccination coverage are increased, sometimes by 2–3 fold. The WHO has since formalized this approach as controlled temperature chain (CTC), where vaccines able to withstand room temperatures (up to 40 °C (104 °F) for days) and used for campaigns or special delivery (not routine immunization) are considered for approval. MenAfriVac was licensed (prequalified) for CTC in 2012 and has seen great success in the African meningitis belt. As of 2021, the only other CTC-prequalified vaccine is Gardasil which is yet to see wide use. PCV13 was CTC approved until 2016 when it was removed to allow consistent labeling.
=== Spray drying === King later turned to spray drying of beverages and other liquids, for which the loss of volatile flavor and aroma substances occurs largely in the spray-nozzle zone, where the droplets to be dried are formed. King and his colleagues examined factors influencing the loss of volatile flavors and aroma and also the factors affecting the development of particle morphology (size, shape, porosity, and thus the bulk density) of the dried product. They interpreted the factors that cause spray-dried particles to be sticky. In later research, King and his colleagues created a device to enable simultaneous measurement of particle morphology and loss of volatile components as the drying of single drops to particles took place. This research was supported by the National Science Foundation. He prepared review articles on retention of volatile flavor and aroma components during spray drying. In later research, King and his colleagues created a device to enable simultaneous measurement of particle morphology and loss of volatile components as the drying of single drops to particles took place.
the side lengths a, b, and c; the semiperimeter s = a + b + c/2 (half the perimeter p); the angle measures A, B, and C of the angles of the vertices opposite the respective sides a, b, and c (with the vertices denoted with the same symbols as their angle measures); the values of trigonometric functions of the angles; the area T of the triangle; the medians ma, mb, and mc of the sides (each being the length of the line segment from the midpoint of the side to the opposite vertex); the altitudes ha, hb, and hc (each being the length of a segment perpendicular to one side and reaching from that side (or possibly the extension of that side) to the opposite vertex); the lengths of the internal angle bisectors ta, tb, and tc (each being a segment from a vertex to the opposite side and bisecting the vertex's angle); the perpendicular bisectors pa, pb, and pc of the sides (each being the length of a segment perpendicular to one side at its midpoint and reaching to one of the other sides); the lengths of line segments with an endpoint at an arbitrary point P in the plane (for example, the length of the segment from P to vertex A is denoted PA or AP); the inradius r (radius of the circle inscribed in the triangle, tangent to all three sides), the exradii ra, rb, and rc (each being the radius of an excircle tangent to side a, b, or c respectively and tangent to the extensions of the other two sides), and the circumradius R (radius of the circle circumscribed around the triangle and passing through all three vertices).
Sources: en.wikipedia.org
He has faced a total of "25 arrests, 35 detoxes, and more than 200 hospital visits." A planned Australian and New Zealand Pentagram tour scheduled for August 2025 was cancelled upon local feminist groups learning about Liebling's conviction.
== Education == McAlpine was awarded an honours bachelor's degree at Western University where she won a gold medal in zoology. She received a master's degree from the University of Toronto in 1966. Her thesis was called An assessment of the creatine kinase test in the detection of carriers of Duchenne muscular dystrophy. She went on to complete a PhD at University College London in 1970 with a thesis entitled Studies on the genetic variation of phosphoglucomutase in man. McAlpine was mentored and supervised by women in her field throughout her education. Her undergraduate work was performed under Helen Battle, and Margaret Thompson was her advisor in Toronto. Her PhD supervisor was Harry Harris.
== History == In the late 1950s and early 1960s, the French molecular biologists François Jacob and Jacques Monod became the first to explain enzyme induction, in the context of the lac operon of Escherichia coli. In the absence of lactose, the constitutively expressed lac repressor protein binds to the operator region of the DNA and prevents the transcription of the operon genes. When present, lactose binds to the lac repressor, causing it to separate from the DNA and thereby enabling transcription to occur. Monod and Jacob generated this theory following 15 years of work by them and others (including Joshua Lederberg), partially as an explanation for Monod's observation of diauxie. Previously, Monod had hypothesized that enzymes could physically adapt themselves to new substrates; a series of experiments by him, Jacob, and Arthur Pardee eventually demonstrated this to be incorrect and led them to the modern theory, for which he and Jacob shared the 1965 Nobel Prize in Physiology or Medicine (together with André Lwoff).
Portal 2 development was restarted specifically to keep the portal concept but adding new elements to freshen the gameplay. During this period, Valve had witnessed another student project out of DigiPen, Tag: The Power of Paint, which allows the player to spray paint onto surfaces to alter their behavior. The team was brought into Valve, though not initially as part of the Portal franchise. The Tag team had found a way to incorporate their paints with real-time fluid dynamics code previously made by Valve, and the concept became the "conversion gels" found in Portal 2. Valve included a co-operative play mode, based on their own observations and stories from players about working out the solutions to Portal's puzzles in a group environment. With this feature, they sought the ability to enable cross-platform play of Portal 2 between computers and consoles through Steamworks. This led to a surprise reveal by Newell that Portal 2 would be released on the PlayStation 3, despite previously expressing how he felt about the difficulties in supporting the console, and that it would include support for cross-platform play between the PC and PS3 versions through a limited Steamworks interface. Valve brought in writer Jay Pinkerton, who had formerly worked on National Lampoon, as well as Left 4 Dead writer Chet Faliszek to assist Wolpaw with the larger story.
== External links == Clinical trial number NCT05662332 for "A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) (QWINT-1)" at ClinicalTrials.gov Clinical trial number NCT05362058 for "A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2)" at ClinicalTrials.gov Clinical trial number NCT05275400 for "A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin" at ClinicalTrials.gov Clinical trial number NCT05462756 for "A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (QWINT-4)" at ClinicalTrials.gov
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.